Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Copyright © 2020. Published by Elsevier Inc..

BACKGROUND: Outcomes of therapy targeting molecular driver alterations detected in advanced non-small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive.

PATIENTS AND METHODS: We performed a multicenter retrospective review of patients with unresectable stage IIIB to IV NSCLC who received matched therapy after a targetable driver alteration was identified using a commercial ctDNA assay through usual clinical care. Eligible patients must not have received targeted therapy prior to ctDNA testing (prior chemotherapy or immunotherapy was permitted). Kaplan-Meier analysis was used to estimate the median duration of targeted therapy. Patients still on targeted therapy were censored at last follow-up.

RESULTS: Seventy-six patients met inclusion criteria. The median age of diagnosis of NSCLC was 64.5 years (range, 31-87 years), 67% were female, 74% were never-smokers, and 97% had adenocarcinoma histology. Twenty-one (28%) patients received systemic treatment prior to targeted therapy, including chemotherapy (n = 17), immunotherapy (n = 5), and/or a biologic (n = 4). Thirty-three (43%) patients remain on targeted therapy at the time of data analysis. The median time on targeted therapy was similar to what has been reported for tissue-detected oncogenic driver mutations in the targeted therapy-naive setting.

CONCLUSIONS: Patients with ctDNA-detected drivers had durable time on targeted therapy. These treatment outcomes data compliment previous studies that have shown enhanced targetable biomarker discovery rates and high tissue concordance of ctDNA testing when incorporated at initial diagnosis of NSCLC. Identification of NSCLC driver mutations using well-validated ctDNA assays can be used for clinical decision-making and targeted therapy assignment.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:21

Enthalten in:

Clinical lung cancer - 21(2020), 6 vom: 03. Nov., Seite 545-552.e1

Sprache:

Englisch

Beteiligte Personen:

Reckamp, Karen L [VerfasserIn]
Patil, Tejas [VerfasserIn]
Kirtane, Kedar [VerfasserIn]
Rich, Thereasa A [VerfasserIn]
Espenschied, Carin R [VerfasserIn]
Weipert, Caroline M [VerfasserIn]
Raymond, Victoria M [VerfasserIn]
Santana-Davila, Rafael [VerfasserIn]
Doebele, Robert C [VerfasserIn]
Baik, Christina S [VerfasserIn]

Links:

Volltext

Themen:

Biomarkers, Tumor
Circulating Tumor DNA
Genotype directed therapy
Journal Article
Liquid biopsy
Lung cancer
Multicenter Study
Oncogene
Research Support, N.I.H., Extramural

Anmerkungen:

Date Completed 11.10.2021

Date Revised 16.07.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.cllc.2020.06.015

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM312417039